Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception

Contraception

Volumn 80, Issue 2, 2009, Pages 128-132

  Beksinska, Mags E ^a   Kleinschmidt, Immo ^b   Smit, Jenni A ^a   Farley, Timothy M M ^c   Rees, Helen V ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c WORLD BANK   (United States)

Author keywords

Adolescents; Bone mineral density; COCs; DMPA; NET EN; Young women

Indexed keywords

ESTROGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; GROUPS BY AGE; HIP; HORMONAL CONTRACEPTION; HUMAN; LOW DRUG DOSE; NORMAL HUMAN; SPINE; TREATMENT DURATION;

BONE DISEASES, METABOLIC; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, COMBINED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDROXYPROGESTERONE 17-ACETATE; NORETHINDRONE; TIME; YOUNG ADULT;

EID: 67650930140     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.02.001     Document Type: Article

References (29)

1. Petitti D.B., Piaggio G., Mehta S., Cravioto M.C., and Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. J Obstet Gynaecol 95 (2000) 736-743
2. Scholes D., Lacroix A.Z., Ott S.M., Ichikawa L.E., and Barlow W.E. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. J Obstet Gynaecol 93 (1999) 233-238
3. Wanichsetakul P., Kamudhamas A., Watanaruagkovit P., Siripakam Y., and Visutakul P. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 65 (2002) 407-410
4. Curtis K.M., and Martins S.L. Progestogen-only contraception and bone mineral density. Contraception 73 (2006) 470-487
5. Cundy T., Evans M., Roberts H., Waltie D., Ames R., and Reid I.R. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 303 (1991) 13-16
6. Scholes D., Lacroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception 69 (2004) 99-104
7. Cromer B.A., McArdle Blair J., Mahan J.D., Zibners B.S., and Naumovski Z. A prospective comparison of bone density in adolescent girls recieving depot medroxyprogesterone accetate (Depo-Provera), levenogesterol (Norplant), or oral contraceptives. J Pediatr 29 (1996) 671-676
8. Busen N.H., Britt R.B., and Rianon M. Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health 32 (2003) 257-259
9. Lara-Torre E., Edwards C.P., Perlman S., and Hertweck S.P. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 17 (2004) 17-21
10. Cromer B.A., Stager M., Bonny A., et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 35 (2004) 434-441
11. Cromer B.A., Bonny A., Stager M., et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril (2008) Epub ahead of print
12. Scholes D., Lacroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 159 (2005) 139-144
13. Clark M.K., Sowers M.R., and Levy B. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril 86 (2006) 1466-1474
14. Rosenburg L., Zhang Y., Constant D., et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception 76 (2007) 425-431
15. Beksinska M.E., Kleinschmidt I., Smit J., and Farley T.M.M. Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogerterone acetate, or combined oral contraceptives for contraception. Contraception 75 (2007) 438-443
16. Martins S.L., Curtis K.M., and Glasier A.F. Combined hormonal contraception and bone health: a systematic review. Contraception 73 (2006) 445-469
17. Hartard M., Kleimond C., Wiseman M., Weissenbacher E.R., Felsenberg D., and Erben R.G. Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone 40 (2006) 444-450
18. Polatti F., Perotti F., Felippa N., Gallina D., and Nappi R.E. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception 51 (1995) 221-224
19. Kaunitz A.M., Miller P.D., Montgomery Rice V., Ross D., and McClung M.R. Bone mineral density in women aged 25-35 years receiving depot-medroxyprogesterone acetate: recovery following discontinuation. Contraception 74 (2006) 90-99
20. Scholes D., LaCroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 13 (2002) 581-587
21. Black Box warning added concerning long-term use of Depo-Provera contraceptive injection. FDA Talk Paper T04-50, November 17, 2004. http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html (accessed October 2, 2006).
22. Faculty of Family Planning and Reproductive Health Care of The Royal College of Obstetricians and Gynaecologists. 2004, Statement on MHRA guidance on Depo-Provera for prevention of postmenopausal bone loss. FFPRHC 2004. http://www.ffprhc.org.uk/admin/uploads/Depo_Provera_alert_statement.pdf (accessed October 2, 2006).
23. Beksinska M.E., Kleinschmidt I., Smit J., and Farley T.M.M. Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogerterone acetate, or combined oral contraceptives and after discontinuation of norethisterone enanthate. Contraception 79 (2009) 345-349
24. Polaneczky M., and Liblanc M. Long-term depot medroxyprogesterone acetate (Deo-Provera) use in inner-city adolescents. J Adolesc Health 2 (1998) 81-88
25. Albertazzi P., Bottazzi M., and Steel S. Bone mineral density and depot medroxyprogesterone acetate. Contraception 73 (2006) 577-583
26. Berenson A.B., Rahman M., Breitkopf C.R., and Bi L.X. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol 112 (2008) 788-799
27. Kaunitz A.M., Arias R., and McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 77 (2008) 67-76
28. World Health Organisation. Medical eligibility criteria for contraceptive use Third edition (2004), Department of Reproductive Health and Research, World Health organization, CH-1211, Geneva 27 Switzerland
29. Society for Adolescent Medicine. Depot medroxyprogesterone acetate and bone mineral density in adolescents - the Black Box warning: a position paper of the Society for Adolescent Medicine. J Adolesc Health 39 (2006) 296-301